


*An Introduction to  
Mass-Spectrometry-Based Proteomics*




Nick Till


MacMillan Group Meeting 07/29/2020

# The Broader Context for MS-Based Proteomics


## Protein-Interaction Networks




## Subcellular Localization




## Activity-based Profiling



## Biomarker Discovery



## *The Broader Context for MS-Based Proteomics*



**proteomics:** the study of proteomes and their functions (or the large scale study of proteins)


*protein measurements can be direct read-outs of biological activity*

# The Broader Context for MS-Based Proteomics




RNAseq: transcript levels with good coverage

*transcript levels can be misleading  
in predicting protein levels*



- translational efficiency
- post-translational modifications
- protein degradation kinetics can vary

## The Broader Context for MS-Based Proteomics





**p53 regulation:** mediated by phosphorylation and proteasomal degradation



***p53 mRNA transcript levels are a poor indicator of p53 levels and activity***

# The Broader Context for MS-Based Proteomics




**MS-based proteomics:** often the tool of choice for large-scale analysis of protein levels and interactions


# *An Overview of Topics Covered*

- Part 1: basic workflow and technology for discovery proteomics
  - How proteins are handled and analyzed
  - Data Peptide assignment and protein inference
  
- Part 2: methods for (relative) quantitative proteomics
  - Label-free methods
  - Whole-cell isotopic labeling strategies
  - Chemical mass tags
  
- Part 3: targeted proteomics and its application to biomarker discovery


*Technology Development and Workflow for MS Proteomics*



*cells or tissue sample*




*proteins*



*proteome analysis*




# Technology Development and Workflow for MS Proteomics




*~ 20,000 proteins*

*(not counting PTMS, alternative splicing)*




*window  $\approx 1500$  m/z*





*direct injection results in high complexity MS*

*separation step necessary prior to MS analysis*

# Technology Development and Workflow for MS Proteomics



# Technology Development and Workflow for MS Proteomics



**MS analysis of peptides**



- protein MW > 10,000 Da
- poor recovery by LC

- peptide MWs < 4,000 Da
- good recovery across peptides

**“bottom-up proteomics”**


peptide fragments  
(incomplete)




protein identity

data analysis involves  
reconstructing protein  
**(protein inference)**

# Technology Development and Workflow for MS Proteomics



**trypsin cleavage:** high-specificity serine protease cleaves after K (lysine) or R (arginine) residues



# Technology Development and Workflow for MS Proteomics

N-terminus–AVTKWGS**R**AGPAVT**K**EIGAASTQV**R**AGDSLQPK**G**TVALER

N-terminus–AVTK

WGS**R**

AGPAVT**K**

EIGAASTQV**R**

AGDSLQPK**K**

GTVALER**R**

} *tryptic peptides*


**large mixture of tryptic peptides are then subjected to LC/MS<sup>2</sup> analysis**

protease	cleavage specificity <sup>a</sup>
trypsin	-K,R-↑-Z- not -K,R-↑-P-
endoproteinase Lys-C	-K-↑-Z-
chymotrypsin	-W,F,Y-↑-Z- and -L,M,A,D,E-↑-Z- at a slower rate
subtilisin	broad specificity to native and denatured proteins
elastase	-B-↑-Z-
endoproteinase Lys-N	-Z-↑-K-
endoproteinase Glu-C	-E-↑-Z- and 3000 times slower at -D-↑-Z-
endoproteinase Arg-C	-R-↑-Z-
endoproteinase Asp-N	-Z-↑-D- and -Z-↑-cysteic acid- but not -Z-↑-C-
proteinase K	-X-↑-Y-
OmpT	-K,R-↑-K,R-

<sup>a</sup>B – uncharged, nonaromatic amino acids (i.e., A, V, L, I, G, S)


X – aliphatic, aromatic, or hydrophobic amino acids; and Z – any amino acid.

## cysteine capping step often included




# Technology Development and Workflow for MS Proteomics

## MS-proteomics sample preparation and workflow




## common context-specific modifications




# Technology Development and Workflow for MS Proteomics

**MS/MS (MS<sup>2</sup>) analysis:** peptides are further fragmented into ions for sequence identification




- multiple methods for MS/MS analysis
  - QqQ (triple quadrupole)
  - Q-TOF (quadrupole time-of-flight)
  - Q Exactive (quadrupole orbitrap)
- multiple modes of fragmentation
  - CID (collision-induced dissociation)
  - ECD (electron-capture-dissociation)
  - observed ions depend on method

## Q Exactive setup (Thermo Fisher)





# Technology Development and Workflow for MS Proteomics





*this is an idealized picture, in reality fragmentation is incomplete and requires more analysis for peptide ID*



# Technology Development and Workflow for MS Proteomics



*low intensity  
low score*



**observed peptide MS<sup>2</sup> spectra** are scored against database MS<sup>2</sup> spectra to identify parent ion

■ SEQUEST


■ MASCOT

■ OMSSA

■ X!Tandem


■ MaxQuant

# Technology Development and Workflow for MS Proteomics




In bottom-up MS-proteomics, peptides (*not proteins*), are directly measured

**Protein inference** is the process of extrapolating protein information from peptide measurements




# Technology Development and Workflow for MS Proteomics

## *A and B can be identified*



## *B cannot be identified*



## *sequence homology complicates analysis*

- protein families
- alternative splicing
- protein isoforms (and point mutations)


## *peptide signal poses additional challenge*

- low intensity ions (especially with DDA)
- small proteins (few tryptic sites)
- PTMs suppress signal


**>30% of protein assignments are made based on a single peptide ID**

# Technology Development and Workflow for MS Proteomics

## protein sequence coverage



## observed peptides in experiments



*peptide coverage information and much more available on proteomics databases*

■ jPOST

■ MassIVE

■ ProteomicsDB

■ PeptideAtlas

■ MaxQB

# *An Overview of Topics Covered*


- Part 1: basic workflow and technology for discovery proteomics
  - How proteins are handled and analyzed
  - Data Peptide assignment and protein inference
  
- Part 2: methods for (relative) quantitative proteomics
  - Label-free methods
  - Whole-cell isotopic labeling strategies
  - Chemical mass tags
  
- Part 3: targeted proteomics and its application to biomarker discovery

# Methods and Applications of Quantitative MS-Proteomics


*Mass spectrometry is not inherently quantitative...*

**Digestion efficiency is protein-dependent:**

*relative amounts of A and B may not  
be reflected by [peptide]*




**Ionization efficiencies vary by >100-fold**



**Matrix effects can change signal intensity (as for all MS)**

# Methods and Applications of Quantitative MS-Proteomics

## Method 1: label-free quantitative proteomics




- Spectral counting or XIC used to compare abundances of a protein
- Housekeeping proteins are typically utilized for concentration normalization
- Many experimental arms can be compared, but many replicates (high  $n$ ) often needed

# Methods and Applications of Quantitative MS-Proteomics

## Method 1: label-free quantitative proteomics

**Data-dependent acquisition (DDA):** only the highest intensity MS<sup>1</sup> precursor ions are selected for MS<sup>2</sup> analysis



*10-20 most intense ions pass to CID cell per MS<sup>1</sup> scan (previously 3-8)*


**Spectral counting:** instances of peptide MS<sup>1</sup> ion observation (verified by MS<sup>2</sup>) summed up for *relative* quantitation

or

**Extracted ion chromatogram (XIC):** integrate ion intensity vs. time plot to quantitate peptide (MS<sup>1</sup>)




# Methods and Applications of Quantitative MS-Proteomics




$v_g$ : gas flow directs ions into TIMS (trapped ion mobility spectrometer)

$E$ : electric field opposes gas flow, causing ion trapping



**ions eluted by ramping  
down electric field strength**

mobility depends on  
collisional cross section (CCS)



# Methods and Applications of Quantitative MS-Proteomics

## Advantages of TIMS-TOF technology

Added dimension of separation




Faster scanning speed



Deeper protein coverage




(can ID 2000 proteins from 10 cells of material)

## Separation based on CCS is impressive





# Methods and Applications of Quantitative MS-Proteomics

## Method 2: stable isotope labeling with amino acids in cell culture (SILAC)



IWHHTFYNELR



*controls for ionization efficiency*

*differences and matrix effects*

*trypsin cut sites*



...AVTKWGS**R**AGPAVT**K**EIGAASTQV**R**AGDSLQP**K**GTVALER...




<sup>13</sup>C<sub>6</sub>Lys and <sup>13</sup>C<sub>6</sub><sup>15</sup>N<sub>2</sub>Arg are optimal

# Methods and Applications of Quantitative MS-Proteomics

## SILAC is well-suited to measure protein turnover kinetics



- heavy peptide signal decreases with time
- light peptide signal increases with time




# Methods and Applications of Quantitative MS-Proteomics

## SILAC is well-suited to measure protein turnover kinetics


No.	Mass	Sequence	Protein	Complete turnover time	$t_{1/2}$
	<i>amu</i>			<i>h</i>	<i>h</i>
1	1210.7	LLLDVPTAAVQA	$\gamma$ -Interferon-inducible protein IP-30 precursor	6	3
2	1011.5	LLLDVPTAAV	$\gamma$ -Interferon-inducible protein IP-30 precursor	6	3
3	951.6	LLGPRLVLA	TMP21; transmembrane trafficking protein	6	3
4	965.6	ALATLIHQV	COP9 complex subunit 7a	6	5
5	913.6	GLLGLTVQL	Catenin $\beta$ 1	6	5
6	868.5	LLIPGLATA	NADH dehydrogenase (ubiquinone) 1 $\alpha$ subcomplex	6	5
7	861.5	ILGPTFTL	3-Hydroxy-3-methylglutaryl-coenzyme A reductase	6	5
8	1037.7	KLLEPVLLL	Similar to 40 S ribosomal protein S16	6	5
9	1034.6	FVFPGELLL	Solute carrier family 1 (neutral amino acid transporter), member 5	6	4
10	910.5	ALPPVLTTV	Unnamed protein product	9	?
11	946.5	SLVEEDALA	Hypothetical protein FLJ30668	9	3
12	1079.7	VLLKARLVPA	NPD019	9	4
13	947.5	ALYVAVVNV	Seven-transmembrane domain protein	9	5
14	1121.5	TLWVDPYEV	B-cell translocation protein 1	9	5
15	959.5	SLFPGQVVI	Polymerase (DNA-directed), $\alpha$ (70 kDa)	9	8
16	974.6	AILPTSIFL	SKB1 homolog	9	4
17	846.5	ALSRITSV	Unknown (protein for MGC:14124)	9	5
18	855.5	ALLGGLVNV	Progesterone and adipoQ receptor family member IV	9	6
19	900.5	ALFPGVALL	Protein-disulfide isomerase mER60 precursor	12	8
20	1015.5	FQDPVPLTV	Transcription intermediary factor 1	18	12
21	1032.5	ALPEIFTEL	Similar to eukaryotic translation initiation factor 2, 26 subunit 3 $\gamma$ , 52 kDa	24	4
22	1094.6	SLLPPDALVGL	Sec23 protein	24	11
23	1360.7	ALWDIETGQQTV	Guanine nucleotide-binding protein, $\beta$ -2 subunit	24	12
24	1115.5	SLFEGTWYL	Hydroxymethylglutaryl-CoA synthase	24	15
25	969.6	VIAEILRGV	Nucleolar protein 5A	24	20
26	<b>984.5</b>	<b>ALMPVLNQV</b>	<b>Homolog of yeast mRNA transport regulator 3</b>	<b>48</b>	<b>6</b>
27	908.5	NLDTSVFI	Similar to RIKEN cDNA 2610003J06	48	12
28	1258.6	FLFDGSPTYVL	Fatty-acid synthase	48	15
29	989.5	ILGGSFLGLL	ET putative translation product	48	23
30	968.6	SLLDPVPEV	Similar to RIKEN cDNA G431004K08	48	24
31	<b>1020.6</b>	<b>FLSSVIQNL</b>	<b>Proteasome 26 S non-ATPase subunit 1</b>	<b>96</b>	<b>6</b>
32	<b>1038.6</b>	<b>YLLPAIVHI</b>	<b>DEAD box polypeptide 17 isoform p82; probable RNA-dependent helicase p72</b>	<b>96</b>	<b>11</b>
33	929.5	SLLDKIIGA	Polymerase I and transcript release factor	96	14
34	1049.6	VLMQDLAFL	Unnamed protein product	96	52
35	786.4	SLAGGILGV	Protein similar to heterogeneous nuclear ribonucleoprotein K	?	24

# Methods and Applications of Quantitative MS-Proteomics

## Method 3: chemical labelling with isotopically-labeled tags



## Current state-of-the-art: isobaric mass tags (iTRAQ, TMT)




$$\text{reporter ion} + \text{mass normalizer} = \text{constant}$$

● – sites of  $^{15}\text{N}$  and  $^{13}\text{C}$  labels

# Methods and Applications of Quantitative MS-Proteomics


## Method 3: chemical labelling with isotopically-labeled tags



- Up to 11-plex possible today
- $^{13}\text{C}$  and  $^{15}\text{N}$ , no  $^2\text{H}$  used
- High resolution MS<sup>2</sup> needed

# Methods and Applications of Quantitative MS-Proteomics

PROTACs cause changes in expression levels at the proteome level




*How can these changes be assigned to degradation or transcriptional regulation?*




# Methods and Applications of Quantitative MS-Proteomics

## Combining SILAC and TMT to study protein regulation mechanisms



# Methods and Applications of Quantitative MS-Proteomics




FYTDD1 critical for mRNA nuclear export, hence protein synthesis

off target degradation by JQ1-VHL

# Methods and Applications of Quantitative MS-Proteomics




## MS-based protein stability/small molecule binding assay



***direct interaction between JQ1-VHL and FYTDD1 confirmed,  
new PROTAC prepared without off-target activity***

# Methods and Applications of Quantitative MS-Proteomics


**Reductive Dimethylation:** alternative chemical labeling strategy with stable isotopes




# *An Overview of Topics Covered*

- Part 1: basic workflow and technology for discovery proteomics
  - How proteins are handled and analyzed
  - Data Peptide assignment and protein inference
  
- Part 2: methods for (relative) quantitative proteomics
  - Label-free methods
  - Whole-cell isotopic labeling strategies
  - Chemical mass tags
  
- Part 3: targeted proteomics and its application to biomarker discovery


# Beyond DDA-based Shotgun Proteomics




“holey” data with DDA



low coverage with SRM



better coverage with DIA



**DDA:** most common approach to discovery proteomics, hypothesis-free

**SRM:** accurate, reproducible quantitation of up to ~500 peptides (chosen)

**DIA:** accurate, reproducible, deep coverage, but requires a DDA measurement first

# Technology Development and Workflow for MS Proteomics

**Biomarkers** “generate clinically useful information that could be used to change the course of the disease for a patient”

